In this randomized clinical trial of 2197 patients with rheumatoid arthritis, a statistically significant increase in the rate of DAS28-CRP of 3.2 or less at month 6 was observed with the use of a smartphone application for assessing patient-reported outcomes. The gene discussed is CRP; the disease is rheumatoid arthritis.